Clinical trial for Non-Small Cell Lung Cancer
Official title BBO-11818 in Adult Subjects With KRAS Mutant Cancer
ClinicalTrials.gov ID: NCT06917079
What this study is testing
What is BBO-11818?
an investigational oral medicine being studied as a potential treatment for KRAS‑mutant non‑small cell lung cancer and other solid tumors is designed to inhibit KRAS proteins across multiple KRAS mutations, blocking a key signaling pathway that drives tumor growth
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether BBO-11818 is safe and may help shrink tumors in people with KRAS‑mutant cancers.
- Who it's for
- You may be able to join if you are an adult with a KRAS‑mutant lung, pancreatic, or colorectal cancer that cannot be removed by surgery.
- What's involved
- You will receive the drug in a hospital setting and have blood tests and scans to check how it works and if it causes side effects.
- Time commitment
- The study lasts about 6 months, with regular visits for drug doses, blood draws, and imaging scans.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or...
- Measurable disease by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
- Life expectancy \>24 weeks
- Adequate organ function
You likely can't join if
- Malignancy within the last 2 years as specified in the protocol
- Untreated brain metastases Other inclusion/exclusion criteria are specified in the protocol.
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
- Sacramento, California, United States
- San Diego, California, United States
- San Francisco, California, United States
- New Haven, Connecticut, United States
- Tampa, Florida, United States
- Peoria, Illinois, United States
- Boston, Massachusetts, United States
- New York, New York, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Salt Lake City, Utah, United States
- Seattle, Washington, United States
- Melbourne, Victoria, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States; Sacramento, California, United States; San Diego, California, United States; San Francisco, California, United States; New Haven, Connecticut, United States; Tampa, Florida, United States and 10 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.